Market cap
$1,219 Mln
Recently Viewed
Clear AllMarket cap
$1,219 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
7
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-62 Mln
ROE
-0.3 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-16.5
Debt to Equity
0
Book Value
$--
EPS
$-2.3
Face value
--
Shares outstanding
33,841,200
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Imago Biosciences Inc (IMGO)
| 0.2 | 0.4 | 132.6 | 80.8 | -- | -- | -- |
|
BSE Sensex*
| -9.2 | 4.5 | -6.1 | -2.9 | 8.2 | 9.5 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
|---|---|
|
Imago Biosciences Inc (IMGO)
| 51.6 |
|
S&P Small-Cap 600
| -17.4 |
|
BSE Sensex
| 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Imago Biosciences Inc (IMGO)
|
36.0 | 1,218.6 | 0.0 | -61.6 | -- | -33.1 | -- | 7.0 |
| 15.0 | 521.5 | 68.2 | -29.0 | -35.9 | -88.3 | -- | 18.0 | |
| 0.5 | 7.9 | 1.7 | -30.4 | -1,803.2 | -184.5 | -- | 1.0 | |
| 11.2 | 299.9 | 19.6 | -176.7 | -839.0 | -- | -- | 2.4 |
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow.... Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California. As of January 11, 2023, Imago BioSciences, Inc. operates as a subsidiary of Merck Sharp & Dohme Corp.. Read more
CEO & Director
Dr. Hugh Young Rienhoff Jr., M.D.
CEO & Director
Dr. Hugh Young Rienhoff Jr., M.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Imago Biosciences Inc (IMGO) is $36.01 (NASDAQ) as of 13-Jan-2023 09:30 EDT. Imago Biosciences Inc (IMGO) has given a return of 80.77% in the last 1 years.
Since, TTM earnings of Imago Biosciences Inc (IMGO) is negative, P/E ratio is not available.
The P/B ratio of Imago Biosciences Inc (IMGO) is 7.04 times as on 02-Feb-2023, a 36 premium to its peers’ median range of 5.16 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-8.97
|
1.77
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2021
|
-8.97
|
1.77
|
|
2020
|
--
|
--
|
The 52-week high and low of Imago Biosciences Inc (IMGO) are Rs -- and Rs -- as of 28-Apr-2026.
Imago Biosciences Inc (IMGO) has a market capitalisation of $ 1,219 Mln as on 02-Feb-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Imago Biosciences Inc (IMGO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.